Table 3.
Comparison of PFS and OS of first-line and second-line immunotherapy and targeted therapy according to their Heng and MSKCC risks
| PFS |
OS |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | First-line | p-value | No. | Second-line | p-value | No. | First-line | No. | Second-line | p-value | ||
| MSKCC | Favorable | 21 | 8.5 (1.4-65.6) | < 0.001 | 16 | 12.7 (9.7-15.7) | 0.047 | 22 | 43.1 (18.3-134.7) | 6 | 23.5 (9.8-37.3) | < 0.001 |
| Intermediate | 107 | 10.4 (0.1-68.4) | 42 | 5.6 (3.4-7.8) | 128 | 20.4 (0.4-129.8) | 42 | 13.0 (5.6-20.4) | ||||
| Poor | 35 | 2.3 (0.1-16.2) | 10 | 4.1 (3.3-4.9) | 0.010 | 52 | 5.6 (0.3-156.7) | 10 | 4.6 (2.4-6.8) | |||
| Heng | Favorable | 38 | 9.2 (1.4-65.6) | < 0.001 | 23 | 14.2 (1.4-65.6) | 40 | 32.4 (3.6-149.6) | 23 | 23.5 (13.6-33.4) | < 0.001 | |
| Intermediate | 128 | 3.9 (0.1-68.4) | 48 | 4.6 (2.6-6.6) | 159 | 16.5 (0.3-133.5) | 48 | 14.5 (6.3-22.7) | ||||
| Poor | 27 | 2.7 (0.1-13.3) | 6 | 4.1 (2.9-5.2) | 40 | 6.1 (0.7-156.7) | 6 | 4.6 (2.1-7.1) | ||||
| MSKCC IT | Favorable | 10 | 34.9 (2.1-65.6) | < 0.001 | - | - | - | 2 | 29.8 (29.8-134.7) | - | - | - |
| Intermediate | 54 | 24.6 (0.1-34.0) | - | - | 45 | 21.2 (2.5-129.8) | - | - | ||||
| Poor | 19 | 6.6 (0.1-15.4) | - | - | 22 | 6.0 (2.2-156.7) | - | - | ||||
| MSKCC TT | Favorable | 16 | 39.6 (1.4-63.2) | - | - | 17 | 43.1 (15.6-78.4) | - | - | |||
| Intermediate | 57 | 13.1 (0.2-68.4) | - | - | 70 | 14.6 (0.4-75.5) | - | - | ||||
| Poor | 16 | 4.7 (0.1-16.2) | - | - | 25 | 4.7 (0.3-18.6) | - | - | ||||
| MSKCC ICTx and TT | Favorable | - | - | - | - | 8 | 29.9 (20.4-94.6) | - | - | |||
| Intermediate | - | - | - | - | 16 | 40.8 (5.8-123.5) | - | - | ||||
| Poor | - | - | - | - | 5 | 9 (5.5-39.3) | - | - | ||||
| Heng IT | Favorable | 20 | 9.2 (2-65.6) | < 0.001 | - | - | - | 7 | 66.2 (8.4-149.6) | - | - | - |
| Intermediate | 68 | 6.3 (0.1-34.0) | - | - | 68 | 16.6 (1.0-133.5) | - | - | ||||
| Poor | 17 | 4.1 (0.1-13.3) | - | - | 18 | 5.91 (0.7-156.7) | - | - | ||||
| Heng TT | Favorable | 18 | 22.3 (1.4-63.2) | - | - | 20 | 40.8 (3.6-68.3) | - | - | |||
| Intermediate | 59 | 8.4 (0.1-68.4) | - | - | 72 | 14.1 (0.3-78.4) | - | - | ||||
| Poor | 11 | 4.3 (0.5-9.8) | - | - | 19 | 4.7 (0.9-16.4) | - | - | ||||
| Heng IT and TT | Favorable | - | - | - | - | 13 | 41.9 (8.4-95.8) | - | - | |||
| Intermediate | - | - | - | - | 17 | 40.7 (5.5-123.5) | - | - | ||||
| Poor | - | - | - | - | 3 | 9.0 (7.3-9.2) | - | - | ||||
Values are presented as median (range, mo). PFS, progression-free survival; OS, overall survival; MSKCC, Memorial Sloane Kettering Cancer Center; IT, immunotherapy; TT, targeted therapy; ICTx, immunotherapy.